Your session is about to expire
← Back to Search
Lu AG06466 for Post-Traumatic Stress Disorder
Study Summary
This trial will study the effects of a new drug, Lu AG06466, on people with PTSD. The drug will be given in doses of 30mg.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants is the trial aiming to recruit?
"Affirmative. According to clinicaltrials.gov, this medical research is still recruiting participants after being initially published on September 30th 2020 and last updated June 15th 2022. The project requires the recruitment of 30 individuals from two distinct locations."
Is participation in this research project possible?
"This clinical trial requires the enrolment of 30 individuals between 18 and 55 years old with a confirmed diagnosis of post traumatic stress disorder. For eligibility, they must also have an elevated Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score, alterations in arousal/reactivity as reported on CAPS-5, ongoing sleep disturbances based on CAPS-5 assessment, willingness to abstain from prohibited medications during the study period and completion of a psychotropic medication washout phase. Additionally participants cannot have any contraventions that would preclude MRI scans."
Is this research project accommodating participants who are younger than 45?
"The eligibility requirements for this study stipulate that the minimum age to participate is 18 and no patient can be over 55 years old."
Are there any vacancies available in this clinical experiment?
"Affirmative, the information hosted on clinicaltrials.gov demonstrates that this experiment is currently recruiting participants. It was first revealed to the public on September 30th 2020 and its most recent edition occurred June 15th 2022. This investigation requires a total of 30 volunteers from two sites."
Has the Food and Drug Administration certified Lu AG06466 as safe for use?
"Since this is the first phase of testing, data on Lu AG06466's efficacy and safety are limited. Thus, our team at Power has graded its safety as a 1."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger